EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Fosfomycin as an adjunctive agent against carbapenem-resistant Acinetobacter baumannii: an updated narrative review

Luca Pipitò, Eleonora Bono, Chiara Vincenza Mazzola, Antonio Cascio iD

Infection · 2026-10 · 54 (5) · 2361-2376

DOI: 10.1007/s15010-026-02895-8 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Infection, online erschienen am 27.07.2026. Verfasst von Luca Pipitò und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties G D'Alessandro, University of Palermo, Palermo, 9013…. Hauptthemen laut MEDLINE: Fosfomycin, Acinetobacter baumannii, Anti-Bacterial Agents, Acinetobacter Infections. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Palermo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Carbapenem-resistant Acinetobacter baumannii (CRAB) represents a critical therapeutic challenge due to limited effective treatment options and high associated mortality. Fosfomycin has been increasingly investigated as an adjunctive agent in combination regimens, despite its intrinsically reduced activity against A. baumannii . This narrative review summarizes current in vitro, in vivo, and clinical evidence on fosfomycin-containing therapies for CRAB infections. A total of 48 studies were included, encompassing in vitro ( n = 27), animal ( n = 2), and clinical investigations ( n = 20). In one case, both in vitro and clinical data were reported. In vitro data suggest that fosfomycin may exhibit synergistic or additive activity when combined with several anti-CRAB agents, most consistently with sulbactam, imipenem, and colistin, although results are highly heterogeneous and method-dependent. Although limited, in vivo studies indicate improved bacterial clearance with fosfomycin-based combinations, particularly in pneumonia models. Clinical evidence remains largely observational and non-randomized, frequently involving critically ill patients receiving multiple combination therapies. While some multicenter studies, particularly from Italian cohorts, report improved clinical outcomes and survival associated with fosfomycin-containing regimens, especially in combination with cefiderocol, other studies do not confirm a clear benefit. Clinical trials have mainly demonstrated improvements in microbiological response and early infection control, without consistent effects on mortality. Overall, current evidence suggests that fosfomycin may provide additional benefit when incorporated into selected combination regimens for CRAB infections, although its independent contribution remains uncertain. Among the evaluated regimens, cefiderocol-fosfomycin combinations currently appear to be supported by the most encouraging observational clinical evidence, particularly regarding early clinical response and microbiological control.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FosfomycinAcinetobacter baumanniiAnti-Bacterial AgentsAcinetobacter InfectionsCarbapenemsHumansAnimalsDrug Therapy, CombinationDrug Synergism

Stichwörter der Autor:innen

Antibiotic synergyAntimicrobial resistanceCarbapenem-resistant Acinetobacter baumanniiClinical outcomesCombination therapyFosfomycin

Substanzen

FosfomycinAnti-Bacterial AgentsCarbapenems

Autor:innen und Institutionen

  • Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties G D'Alessandro, University of Palermo, Palermo, 90133, Italy.
  • Infectious and Tropical Disease Unit, AOU Policlinico P. Giaccone, Palermo, 90127, Italy.
  • Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties G D'Alessandro, University of Palermo, Palermo, 90133, Italy. antonio.cascio03@unipa.it.
  • Infectious and Tropical Disease Unit, AOU Policlinico P. Giaccone, Palermo, 90127, Italy. antonio.cascio03@unipa.it.

ORCID-Profile: Antonio Cascio

Förderung

  • Università degli Studi di Palermo

Zitieren

APA

Pipitò, L., Bono, E., Mazzola, C. V., & Cascio, A. (2026). Fosfomycin as an adjunctive agent against carbapenem-resistant Acinetobacter baumannii: an updated narrative review. Infection, 54(5), 2361-2376. https://doi.org/10.1007/s15010-026-02895-8

Vancouver

Pipitò L, Bono E, Mazzola CV, Cascio A. Fosfomycin as an adjunctive agent against carbapenem-resistant Acinetobacter baumannii: an updated narrative review. Infection. 2026;54(5):2361-2376. doi:10.1007/s15010-026-02895-8

BibTeX
@article{Pipit2026,
  author = {Pipitò, Luca and Bono, Eleonora and Mazzola, Chiara Vincenza and Cascio, Antonio},
  title = {Fosfomycin as an adjunctive agent against carbapenem-resistant Acinetobacter baumannii: an updated narrative review},
  journal = {Infection},
  year = {2026},
  volume = {54},
  number = {5},
  pages = {2361--2376},
  doi = {10.1007/s15010-026-02895-8}
}
Kostenlos starten →